

ChroMedX Strengthens Advisory Board with New Appointments

April 12, 2017 – ChroMedX Corp. (the “**Company**”) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the appointment of Dr. Brian William Cameron and John P. Ormston to the Company’s advisory board.

"We are very pleased to strengthen our advisory board with the appointment of John Ormston and Dr. Cameron. Dr. Cameron’s practical experience and John’s legal expertise adds diversity to our knowledge base that will be very important as the Company moves into the next development phase," said Ash Kaushal, President & CEO, ChroMedX Corp.

John P. Ormston earned his Bachelor of Law degree from University of Western Ontario in 1993 and Bachelor of Business Administration from Wilfrid Laurier University in 1989. Mr. Ormston has extensive trial experience in a wide variety of commercial matters, including shareholder disputes, breach of contract, economic torts as well as extensive employment law experience acting for both employers and employees. He is a member of the Advocates’ Society and is a past Chair of the Board of Governors of Wilfrid Laurier University. John is a former litigation partner from Gowling Lafleur Henderson LLP and current partner at Ormston List Frawley LLP that specializes in corporate, securities, and commercial litigation/employment law in the technology, Junior resource and finance sectors.

“I am excited to join ChroMedX and play a part in providing a practical user perspective. I think the analysis the HemoPalm offers now is only scratching the surface and I look forward to advising the Company in expanding its use and application," said Dr. Brian Cameron.

Dr. Brian W. Cameron BSc. MD. CCFP has over 30 of years experience in family practice, hospitalist and long term care medicine. Dr. Cameron earned his Doctorate of Medicine from University of Calgary in 1982 and Bachelor of Science with Honors in Biology and Neurophysiology in 1978. Brian currently provides family medicine in Burlington, Ontario and is active in teaching medical students through McMaster University Medical School.

About ChroMedX Corp.

ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company’s issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

The HemoPalm Handheld Blood Analyzer System is the only handheld blood analysis technology which combines Blood Gases & Electrolytes with full CO-oximetry. Currently this combination is not available on any of the handheld analyzers on the market. Existing

technologies require users to purchase a second device to carry out the CO-oximetry. The Company's technology has the advantage of being able to offer a single handheld blood analyzer that provides all the required tests for Blood Gases & Electrolytes, with full CO-oximetry and bilirubin. Another competitive advantage of the HemoPalm system will be its ability to draw capillary blood directly from a pin-prick site into the cartridge, providing an alternative to arterial blood. Drawing arterial blood is painful and can cause nerve damage. CO-oximetry is the measurement of five different hemoglobin species in blood.

The global market for Blood Gases & Electrolytes was estimated to be 1.5 Billion \$US in 2015 and is projected to reach over 1.8 Billion by 2020.

Website: www.chromedx.com

Contact:

Investor Relations
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
investor.relations@chromedx.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com